Come meet Daniel Teper, PharmD, MBA, the Co-Founder, Chairman & Chief Executive Officer, of Cytovia Therapeutics, a company that aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology.

These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company's own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF).

Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

Find out more at www.cytoviatx.com 

Learn More

We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Thursday, April 15th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "Revolutionizing The Treatment of Kidney Disease."

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events

We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Wednesday, April 13 (8:30 am PT/ 11:30 am ET). Our events are approximately 30 minutes in duration.

Mr. Steve Shum, Chief Executive Officer in CEO of INVO Bioscience (NASDAQ: INVO) will deliver a presentation titled "Democratizing Infertility - A Severely Underserved Global Market." He will be also be available for a 5-10 minute Q&A session at the end of the presentation. Send Questions to email: research@tribepublic.com.

INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.

Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI).

Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care.

Back to Events

We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Tuesday, January 26th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "ALIGNED in the Fight Against Kidney Diseases"

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events

Palo Alto-based Finjan (NASDAQ: FNJN), established over 20 years ago, is a globally recognized pioneer in cybersecurity. Finjan's inventions are embedded within a strong portfolio of patents focusing on software and hardware technologies capable of proactively detecting previously unknown and emerging threats on a real-time, behavior-based basis. Finjan continues to grow through investments in innovation, strategic acquisitions, and partnerships promoting economic advancement and job creation.

Finjan Mobile is committed to incorporating Finjan's enterprise-grade technology into products that increase Internet security for our customers using mobile devices. Finjan Mobile listens to customer's feedback, innovates in response to that feedback and new challenges, and looks for both organic and inorganic paths towards future growth.

Finjan Blue, Inc., a wholly owned subsidiary of Finjan Holdings, has entered into a patent acquisition and development agreement with IBM, and includes pathways for the two companies to consider development efforts in the future. The Agreement, the terms of which are confidential, includes the transfer of select security-related patent assets and provides for the sharing of pertinent institutional knowledge and resources by IBM to Finjan Blue.

Finjan Mobile’s most recent launch is the InvinciBull VPN Browser which is built-off Finjan’s patented technology. InvinciBull is the only mobile app to integrate a VPN with a secure, feature-rich browser. The Virtual Private Network (VPN) keeps consumers data safe by encrypting all internet traffic when using public Wifi in a coffee shop, hotel or airport hotspot.